{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:39:46Z","timestamp":1790699986299,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,27]],"date-time":"2023-06-27T00:00:00Z","timestamp":1687824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.gore.2023.101235","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T13:53:56Z","timestamp":1687960436000},"page":"101235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Esophagitis as a complication of the combination of lenvatinib and pembrolizumab for advanced endometrial cancer: A case report"],"prefix":"10.1016","volume":"49","author":[{"given":"Massine","family":"Fellouah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Auclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Fortin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9mie","family":"Berdugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"de Guerk\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2023.101235_b0005","unstructured":"American Cancer Society Endometrial Cancer Risk Factors. https:\/\/www.cancer.org\/cancer\/endometrial-cancer\/causes-risks-prevention\/risk-factors.html."},{"key":"10.1016\/j.gore.2023.101235_b0010","unstructured":"American Cancer SocietyEndometrial cancer survival rates, by stage. https:\/\/www.cancer.org\/cancer\/endometrial-cancer\/detection-diagnosis staging\/survival-rates.html."},{"key":"10.1016\/j.gore.2023.101235_b0015","unstructured":"American Cancer SocietyKey statistics for endometrial cancer. https:\/\/www.cancer.org\/cancer\/endometrial-cancer\/about\/key-statistics.html."},{"issue":"1","key":"10.1016\/j.gore.2023.101235_b0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.seminoncol.2018.11.004","article-title":"Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer","volume":"46","author":"Cabanillas","year":"2019","journal-title":"Semin Oncol."},{"issue":"23","key":"10.1016\/j.gore.2023.101235_b0025","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N Engl J Med."},{"issue":"2","key":"10.1016\/j.gore.2023.101235_b0030","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1634\/theoncologist.2019-0407","article-title":"Lenvatinib in Management of Solid Tumors","volume":"25","author":"Hao","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.gore.2023.101235_b0035","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer."},{"issue":"11","key":"10.1016\/j.gore.2023.101235_b0040","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok","year":"2016","journal-title":"Human vaccines & immunotherapeutics"},{"issue":"26","key":"10.1016\/j.gore.2023.101235_b0045","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"JCO"},{"issue":"5","key":"10.1016\/j.gore.2023.101235_b0050","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl. J. Med."},{"issue":"23","key":"10.1016\/j.gore.2023.101235_b0055","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.gore.2023.101235_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107281","article-title":"Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: a systematic review","volume":"91","author":"Mo","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"14","key":"10.1016\/j.gore.2023.101235_b0065","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus Pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.gore.2023.101235_b0070","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.gore.2023.101235_b0075","doi-asserted-by":"crossref","unstructured":"Suyama, K., & Iwase, H. 2018. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers.Cancer control : journal of the Moffitt Cancer Center,25(1), 1073274818789361. https:\/\/doi.org\/10.1177\/1073274818789361.","DOI":"10.1177\/1073274818789361"}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923001042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578923001042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:59:24Z","timestamp":1762480764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578923001042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":15,"alternative-id":["S2352578923001042"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2023.101235","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Esophagitis as a complication of the combination of lenvatinib and pembrolizumab for advanced endometrial cancer: A case report","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2023.101235","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101235"}}